Check before giving

SO-C-015 says not to give if sildenafil, vardenafil, or tadalafil was taken within the preceding 24 hours.
Recheck BP before repeat doses. I-15 and the condition orders use different boundary wording; this page identifies each condition order explicitly.

Use in OCEMS

Use the chest-pain or respiratory-distress standing order that matches the presentation. Their blood-pressure boundaries differ.
The available SL forms include 0.4 mg tablets, powder packets, and metered sprays.

Indication / route	Dose & limits
Cardiac chest pain — SO-C-015	0.4 mg SL when systolic BP is above 100; repeat about every 3 minutes for discomfort, up to 3 EMS doses while BP stays above 100. Patient self-doses before EMS are not counted in those 3 doses.
Suspected CHF/pulmonary edema — SO-M-035	0.4 mg SL when systolic BP is at least 100; may repeat twice if it remains at least 100. At systolic BP at least 150, use 0.8 mg SL and may repeat twice while it stays at least 150; reduce to 0.4 mg if BP falls below 150 but remains above 100.

No routine pediatric field nitroglycerin regimen is listed in I-20. Do not extrapolate the adult SL rows to children.
Any pre-existing transport infusion requires the applicable transport authorization and sending-facility orders; it is not a pediatric field initiation dose.

No routine pediatric field regimen is supplied by the cited OCEMS sources; do not scale an adult dose by weight.

Weight	OCEMS pediatric dose
Any weight	No general pediatric dose under the cited source; follow the applicable order / medical direction.

Check the formulation: one 0.4 mg dose is not the same as the 0.8 mg pulmonary-edema dose.
PR-225 governs a pre-existing IFT nitroglycerin infusion; use the prescribed pump rate and its monitoring/stop criteria, not these SL doses.

Verify secure access, a working pump, the sending RN/physician’s prescribed rate, and any prior BP problem. Maintain that prescribed infusion rate.
Monitor rhythm and vital signs continuously. If systolic BP falls below 90 or obvious poor perfusion develops, stop the infusion and transport to the nearest appropriate ERC.
Document the rate, monitoring, patient condition, and any stop time/reason at handoff. This continuation pathway is distinct from the SL standing-order doses.